Medical Cannabis in the Treatment of Patients with Autism Spectrum Disorder (1648)

• DOI: 10.1212/wnl.94.15_supplement.1648
• Publication Date: 2023-12-07T05:28:50Z
• Authors: Jennifer McVige; Virginia Headd; Mohammed Alwahaidy; Dylan Lis; Dilpreet Kaur; Brianna Albert; Laszlo Mechtler

Objective: Evaluate efficacy and safety of medical cannabis (MC) for pain epilepsy in patients with autism spectrum disorder (ASD). Background: MC is approved treatment ASD 14 states (not NY). In NY it pain. Common challenges include aggression, self-injurious behavior (SIB), elopement, pain, epilepsy. Some individuals can also have severe symptoms. Most these try multiple medications concerning side effects (SE). This study reports a case series treated MC. Design/Methods: Retrospective chart review 20 (6 epilepsy/14 pain) on included written evaluation by patient or caregiver. Autism/Caregiver Global Impression Change (ACGIC) Scale measuring: 1.Quality life (QOL) 2.Activity limitations 3.Symptoms 4.Mood. A 10-point Likert measured: 1.Chronic change 2.Epilepsy 3.Secondary efficacies. product information: dosing, route, frequency, dispensary, cost reported. Results: Patients had improvement seizure frequency (p =0.0032) severity (p=0.0332). degree overall scale revealed all areas Secondary effects: experienced sleep Each tried an average 6.4 other medications. 50% discontinued reduced the use 3 reported mild adverse SE from MC; no caused discontinuation Conclusions: There paucity research ASD. supports previous while exploring indications behavioral issues QOL patients. Disclosure: Dr. McVige has received personal compensation consulting, serving scientific advisory board, speaking, activities Amgen, Avanir, Depomed, Eli Lilly & Company, Oxtellar, Promius, Supernus, Teva Pharmaceuticals. support Lilly, Gammacore, Impax, Teva, Boston Biomedical, Delmar Pharmaceuticals, Alder Biopharmaceuticals, Harry Dent Family Foundation. Headd nothing to disclose. Alwahaidy Lis Kaur Albert Mechtler Allergan, Biohaven, Biomedical Inc., CellDex, DelMar electroCore, Novartis, Orbis Jushi.